Non-life: Competition authority consider to look at the competition

The DCCA is out with report describing inefficient comp. Could be a drag for Tryg and ALMB despite the industry objections. ALMB drop looks attractive, but it could drag on for two more years.

Gjensidige Forskring ASA: 1 director

A director at Gjensidige Forskring ASA bought 5,000 shares at 233.640NOK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

Realised claims synergies ahead of plan

Realised ~2.1pp (NOK 812m), 2 years ahead of time, 75% in NO. ~50% operational, ~40% fraud & procurement & ~10% RedGo. More synergies will be taken out; consensus could improve '27e CR.

Acquire a 20% COI market stake at 7-9x P/E

Acquire Buysure that has 5-years agreements with real estate agents. A 12.5x P/E payment, but with GJF as risk carrier, more 7-9x. The NOK 430m is 4pp of its solvency; neutral to LT-positive

Norway: Best ideas Q1'25

Nordic non-life insurance – Q4 reporting wrap

Expect further improvements in UW

Gjensidige Forsikring (Hold, TP: NOK230.00) - Long-awaited turnaround

Q4 PTP was NOK1,605m, 2% higher YOY, but with a significant underwriting improvement following 11.6% insurance revenue growth and a 6.5%-points stronger underlying claims ratio YOY. Following price hikes of ~19% for Motor Norway from January, we expect the underwriting performance to drive growth momentum in 2025, closing in on the 2026 combined ratio target of

Massive improvement y-o-y; stock up

Adj. PTP +23% vs IR cons (UW & financials), -1% vs ABGSCe (financials); Expect repricing to continue to filter trough and increase profitability; Cons. est. up 3-6% for 25e-26; stock to follow 3-6%

Market hit it hard for financials

Tryg (Buy, TP: DKK185.00) - Continued repricing momentum

Underwriting continued to improve, helped by recent repricing efforts to mitigate inflation, although a soft investment result led to earnings pressure in Q4. With Private segment premium growth of 6.8% YOY in local currencies, supported by continued momentum from Norwegian motor price hikes, we see Tryg as on track to meet its 2027 combined ratio target of ~81%. We have made limited EPS revisions for 2025–2026e, and reiterate our BUY and DKK185 target price.

Miss Q4 due to financials, reiterate 2027 guidance

PTP -8-10% from softer financials anb just soft UW and premiums;Reiterate 2027 guidance, 2025 premium growth from private/SMEs; Stock -1-2% today, cons.est.rev. minor; softer read-x into GJF

Heads-up for Q4-report 24 January

Repricing set to support profitability

The outlook for strong growth momentum in the Nordic P&C sector remains, with the recent rounds of premium repricing yet to take full effect. Furthermore, underwriting profitability is still a key focus, illustrated by Tryg raising its long-term combined ratio target to ~81% at the 2024 CMD. We believe signs of slowing claims inflation, albeit from high levels, together with mostly normal weather, bode well for Q4 underwriting. We have three BUYs and one HOLD, and highlight Sampo as our top sect...

Nordic non-life Q4 preview: positive R/R in GJF

Best short-term margin expansion

Good underwriting hit by financials

Norway: Best ideas Q4'24

Tryg (Buy, TP: DKK185.00) - Underwriting excellence in focus

Underwriting and capital efficiency remained in focus at Tryg’s 2024 CMD in London. The company lowered its long-term combined ratio target to ~81% and has launched a DKK2bn share buyback programme, following a series of de-risking activities. Despite the strong outlook for continued shareholder distributions, we have reduced our 2025–2026e EPS by 1–3% on somewhat lower financial result than expected. We reiterate our BUY and DKK185 target price.

CMD - plan towards 2027

2027 underwriting result target of DKK 8-8.4bn; DKK 15-16bn normal divi added by SBB of DKK 2bn for '24-'27; Stock likely up 0-2% today driven by share buyback